Trial Results Demonstrate Diagnostic Performance of Aurora Dedicated Breast MRI System Over Whole-Body Breast MRI

October 2, 2012 — A clinical trial published in the October issue of Radiology demonstrates that Aurora Imaging Technology’s 1.5T dedicated breast MRI (magnetic resonance imaging) system led to better diagnostic performance for all metrics (sensitivity, specificity, negative predictive value [NPV], positive predictive value [PPV] and receiver operating characteristic [ROC] area) than has been historically reported in trials for breast MRI on whole-body MRI scanners. In addition, the low frequency of false positive and false negative findings associated with the dedicated breast MRI system allows for use of breast MRI with low risk of patient harm in both the screening and diagnostic environments. The study was managed by ACR Image Metrix, the American College of Radiology’s clinical research organization.

“The results of this multicenter trial validate what we have suspected for many years, which is, using a dedicated MRI system optimized for breast imaging results in superior diagnostic performance. In addition, we were able to demonstrate consistency of performance across a variety of breast imaging centers, university, community hospital and independent breast centers,” said Steven Harms, M.D., primary investigator for the study.

The study included more than 900 patients and resulted in sensitivity and specificity for the dedicated breast MRI system of 92 percent (92/100) and 88.9 percent (741/834), respectively. For all cases, the NPV was 98.9 percent (741/749), and the NPV for screening cases was 100 percent (326/326). The area under the ROC curve was 94.2 percent. The false positive rate was 93/834 (11 percent) for all cases, but only 16/326 (4.7 percent) for the screening cohort.

Alan Hollingsworth, M.D., medical director, breast surgeon at Mercy Women’s Center at Mercy Health Center, and study investigator added, “False positive rates from previously reported trials using whole-body breast MRI have typically been between 30-50 percent. These studies have led to criticism of breast MRI for its high false positive rates, resulting in unnecessary biopsies, surgical procedures and anxiety for the patient. The dedicated breast MRI system offers a significant improvement in performance. Even within the 93 false positives, 25 (27 percent) were high-risk histologies for which excision is often recommended. This kind of performance should provide breast radiologists and surgeons alike a higher level of diagnostic confidence, and could have significant impact on the role of breast MRI”.

For more information: www.auroramri.com

Related Content

Feature | Radiology Business | By Melinda Taschetta-Millane

Did you know that Imaging Technology News (ITN) maintains more than 40 comparison charts of product specifications from ...

Time August 12, 2022
arrow
News | Radiology Education

August 11, 2022 — After a three-year break, this spring featured the return of the anticipated Canon Roadshow Events ...

Time August 11, 2022
arrow
News | Computed Tomography (CT)

August 11, 2022 — For the first time, researchers successfully captured CT images of an entire woolly mammoth tusk ...

Time August 11, 2022
arrow
News | Radiology Imaging

August 11, 2022 — Bracco Imaging S.p.A. has announced the renewal of the “Bracco Fellowships” initiative, in partnership ...

Time August 11, 2022
arrow
News | Ultrasound Imaging

August 10, 2022 — Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ...

Time August 10, 2022
arrow
News | Ultrasound Women's Health

August 10, 2022 — TransMed7, LLC announced that the first clinical cases of the final commercial production version of ...

Time August 10, 2022
arrow
News | Point-of-Care Ultrasound (POCUS)

August 10, 2022 — Mindray North America, a global leader and developer of healthcare technologies and solutions for ...

Time August 10, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — Representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill ...

Time August 08, 2022
arrow
Subscribe Now